Search Results - "Akkurd, D M"

PB1951: INVESTIGATION OF THE RELATIONSHIP BETWEEN CD56 AND CD117 EXPRESSIONS AND CLINICAL AND LABORATORY FINDINGS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS by Akkurd, D. M., Haydaroglu Sahin, H., Yilmaz, E., Okan, V.

Get full text

PB2151: EVALUATION OF BONE MINERAL DENSITY IN LYMPHOMA PATIENTS WITH USING PET/CT AND THE ROLE OF BCL‐2 by Okan, V., Haydaroglu Sahin, H., Gün, H., Akkurd, D. M.

Get full text

P1075: EVALUATION OF CYTOKIN GENE POLYMOPHISMS AND GENE EXPRESSIONS IN PATIENTS WITH HODGKIN LYMPHOMA by Haydaroglu Sahin, H., Demirbas, D. D., Akkurd, D. M., Okan, V.

Get full text

Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML by Ucar, M A, Ozet, G, Koyuncu, M B, Sonmez, M, Akidan, O, Ayli, M, Yildirim, M, Pehlivan, M, Akkurd, D M, Sahin, H, Guvenc, B, Okan, V, Tiftik, E N, Akdeniz, A, Dincyurek, H D, Gunes, A K, Dagdas, S, Acar, H I, Ucar, H K, Tombak, A

“…Relapsed/refractory AML cases are much more resistant to chemotherapy. Venetoclax is a highly sensitive BCL-2 inhibitor. It was aimed to evaluate the effects…”
Get more information